RAD51D mutation
|
Prostate Cancer
|
RAD51D mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
RAD51D mutation
|
Ovarian Cancer
|
RAD51D mutation
|
Ovarian Cancer
|
rucaparib Sensitive: B - Late Trials
|
rucaparib Sensitive: B - Late Trials
|
RAD51D mutation
|
Ovarian Cancer
|
RAD51D mutation
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
RAD51D mutation
|
Small Cell Lung Cancer
|
RAD51D mutation
|
Small Cell Lung Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
RAD51D mutation
|
HER2 Negative Breast Cancer
|
RAD51D mutation
|
HER2 Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
RAD51D mutation
|
Breast Cancer
|
RAD51D mutation
|
Breast Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|